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Hearing impairment is common in patients with mitochondrial disorders, aﬀecting over half of all cases at some time in the course
of the disease. In some patients, deafness is only part of a multisystem disorder. By contrast, there are also a number of “pure”
mitochondrial deafness disorders, the most common probably being maternally inherited. We retrospectively analyzed the last 60
genetically conﬁrmed mitochondrial disorders diagnosed in our Department: 28 had bilateral sensorineural hearing loss, whereas
32 didn’t present ear’s abnormalities, without diﬀerence about sex and age of onset between each single group of diseases. We
reported also a case of MELAS patient with sensorineural hearing loss, in which cochlear implantation greatly contributed to
the patient’s quality of life. Our study suggests that sensorineural hearing loss is an important feature in mitochondrial disorders
and indicated that cochlear implantation can be recommended for patients with MELAS syndrome and others mitochondrial
disorders.
1.Introduction
Mitochondrial diseases are disorders caused by impairment
of the mitochondrial respiratory chain. The genetic error can
aﬀect both mitochondrial DNA (mtDNA) and nuclear DNA
(nDNA) [1].
MtDNA mutations are classiﬁed as either large-scale
rearrangements (partial deletions or duplications), usually
sporadic, or point mutations, which are usually maternally
inherited, and concern genes responsible for protein syn-
thesis (rRNAs or tRNAs), or genes encoding subunits of
the electron transport chain (ETC) [2]. The phenotypic
expression of mtDNA mutations depends on the aﬀected
gene, its tissue distribution, and the diﬀerent dependency
of diﬀerent organs and tissues on the mitochondrial energy
supply. Visual and auditory pathways, heart, central nervous
system (CNS), and skeletal muscle are the tissues mostly
involved, because of their dependence on aerobic energy
production [1].
Hearing impairment is common in patients with mito-
chondrial disorders, aﬀecting over half of all cases at some
time in the course of the disease [3]. Although the ﬁnal
common pathway for the hearing loss is thought to involve
ATP deﬁciency secondary to a biochemical defect of the res-
piratory chain, the clinical presentation of mitochondrial
deafnessvariesconsiderably,bothintermsofassociatedclin-
icalfeaturesandofnaturalhistory.Insomepatients,deafness
is only part of a multisystem disorder, often involving the
central nervous system, neuromuscular system, or endocrine
organs; in other cases, deafness may represent a feature of an
oligosyndromic disease [4].
By contrast, there are also a number of mitochondrial
“pure” deafness disorders, the most common probably being
maternallyinheriteddeafnessduetotheA1555Gmutationin
the 12s rRNA gene, MTRNR1 [5]. The use of streptomycin
and to a lesser extent other aminoglycoside antibiotics can
cause hearing loss in genetically susceptible individuals.2 Genetics Research International
These drugs are known to exert their antibacterial eﬀects at
the level of the decoding site of the small ribosomal subunit,
causing miscoding or premature termination of protein syn-
thesis [6]. The hearing loss is primarily high frequency and
maybeunilateral.Riskfactorsforaminoglycosideototoxicity
include therapy lasting more than 7 days, elevated serum
levels, prior exposure to aminoglycosides, noise exposure,
high daily dose, use in neonates, and a background of predis-
posing mutations. Several mutations in the MTRNR1 gene
encoding the 12S rRNA (961delT/insC, T1095C, C1494T,
A1555G, and possibly A827G, T1005C and A1116G) and
possibly also mutations (G7444A) in the COI/MTTS1 gene
overlap can contribute to ototoxic hearing loss [7–11]. The
MTRNR1 mutations probably alter the secondary structure
of the 12S rRNA molecule, so that it resembles its bacterial
counterpart,the16SrRNA,moreclosely.Asthebacterial16S
rRNA molecule is the target of aminoglycoside action, this
mightexplainthecumulatingeﬀectoftheseMTRNR1muta-
tions and the use of aminoglycosides [12]. Mitochondrial
nonsyndromic sensory neural hearing loss (SNHL) is also
associatedwiththeA7445G, 7472insC, T7510C, and T7511C
mutations in the tRNASer (UCN) gene, MTTS1 [13].
The pathological examination of the inner ear is tech-
nically demanding, highly specialized, and only possible
postmortem. There have, therefore, only been a few detailed
pathological studies of the auditory system in patients with
mitochondrial diseases. In the cochlea, the stria vascularis
maintains the ionic gradient necessary for sound transduc-
tion and the complex interaction between inner and outer
hair cells [14]. These components are highly metabolically
active, and it is likely that a respiratory chain defect and
the attendant relative deﬁciency of intracellular ATP would
impair the function of both the stria and the air cells, ulti-
mately leading to cell death, possibly through apoptosis [15].
Hearing loss is usually peripheral (due to cochlear or
auditory nerve dysfunction), but in patients with a multi-
system mitochondrial disorder, the auditory system may be
aﬀected at the brain stem, midbrain or at a higher level in the
auditory cortex. The peripheral hearing loss typically aﬀects
high frequencies ﬁrst, followed by intermediate frequencies,
and ﬁnally involving low frequencies and causing the typical
“ﬂat” audiogram seen in a severely deaf individual. The
preferential involvement of high frequencies may be related
totherelativelyhighenergyrequirementsofthebasalcochlea
[16]. The vast majority of patients with mitochondrial
deafness have absent otoacoustic emission, providing strong
evidence that the cochlea is the component most sensitive to
mitochondrial dysfunction [17, 18].
In this review, we analyzed the results of a retrospective
study about the presence of hearing loss in a cohort of
patients with genetically conﬁrmed mitochondrial disease
and we described the results and follow-up of a MELAS
patient who underwent cochlear implantation.
2. Patientsand Methods
2.1. Patients. We retrospectively analyzed the last 60 genet-
ically conﬁrmed mitochondrial disorders diagnosed in our
Department in order to identify patients aﬀected with hear-
ingloss.Malesandfemaleswerequiteequallydistributed(33
males and 27 females), with an age at diagnosis ranging from
8 to 73 years; the mean age of this group of patients was 45
years old. Three patients belonged to the same family.
2.2. Methods. Most of patients were referred to our centre
for a suspected mitochondrial disease and underwent a
muscle biopsy (quadriceps or deltoid muscle). In these cases,
DNA was extracted from frozen muscle tissue and used for
direct sequencing of mitochondrial and/or nuclear genes,
with standard methods [19, 20]. In some other cases, family
history was strongly suggestive for mitochondrial disorder
so that patients were not submitted to muscle biopsy, and
DNA to perform molecular analysis was extracted from their
blood.
Presence of single or multiple deletions of mitochon-
drial DNA was revealed by long-range PCR or southern
blot analysis, using standard methods [20]. mtDNA point
mutations were searched by screening the whole mtDNA
using the MitoScreen Assay Kit for the Transgenomic WAVE
System and DHPLC (denaturing high-performance liq-
uid chromatography) with single-stranded conformational
polymorphism analysis, following supplier’s indications or
by using the ABI PRISM BigDye Terminators v3.0 Cycle
Sequencing Kit.
All of the cases included in this study performed audio-
metric examination before to receive the genetic diagnosis.
The cut-oﬀ of hearing loss was deﬁned according to the
mean hearing loss at frequencies of 250, 500, 1000, 2000, and
4000Hz as follows: normal hearing ≤ 20dB hearing loss.
3. Results
Out of the 60 cases, 28 had bilateral sensorineural hearing
loss, whereas 32 did not present ear’s abnormalities. Clinical
ﬁndings and the frequency of SNHL are summarized in
Table 1 and Figure 1. All of the three patients belonging to
the same family had A3243G mitochondrial DNA mutation
and hearing loss.
One of the 28 patients with hearing loss, a MELAS
patient, was submitted to cochlear implantation. Following,
we brieﬂy reported his main clinical notes.
He was a 46-year-old man who started to complain mild
bilateralhearinglossfromhis20;hehadnormalprenataland
perinatal histories. His family history was also normal. Dia-
betes mellitus was noted at the age of 33, and insulin therapy
was initiated. Serum biochemical studies showed a high level
oflacticacidosis,whichincreasedafterexercise,andechocar-
diography disclosed the presence of hypertrophic cardiomy-
opathy. Neurological examination showed diﬀuse mild mus-
cle weakness, more evident in distal lower limbs, with
stepping gait. Computer tomography (CT) and magnetic
resonance imaging (MRI) scans showed no abnormality in
either inner ear. MRI demonstrated mild cerebellar atrophy.
Muscle biopsy revealed strong reactive vessels on Succi-
nate Dehydrogenase stain (SDH), without ragged red neither
citochrome C-oxidase negative ﬁbers. Molecular analysisGenetics Research International 3
Table 1: Clinical and molecular features of patients analyzed in our
study.
Clinical
syndrome Molecular defect Hearing
loss
Non
hearing loss Total
MIDD A3243G 4 0 4
MELAS A3243G 11 10 21
MERRF A8344G 6 1 7
PEO Single deletion (4)
Multiple deletions (20) 42 0 2 4
MNGIE TYMP mutations 3 1 4
MIDD: Mitochondrial inherited ciabetes and deafness; MELAS: mitochon-
drial encephalomyopathy with lactic acidosis and stroke-like episodes;
MERRF: myoclonic epilepsy with ragged red ﬁbers; PEO: progressive
external opthalmoplegia; MNGIE: mitochondrial neurogastrointestinal
Encephalomyopathy.
MERRF
21%
MIDD
14%
MELAS
41%
MNGIE
10%
PEO 14%
Figure 1: Graph of distribution of hearing loss into the clinical syn-
dromes.
revealed the presence of the A3243G mitochondrial DNA
heteroplasmic mutation.
During next years, hearing loss markedly worsened:
pure-tone audiometry revealed bilateral profound hearing
loss with an average of 130dB in both ears. The hearing aid
was no longer useful. In a promontory stimulation test, the
patient responded to electrical stimulation in both ears at the
intensity of 0.3mA.
At 33 years old, he underwent cochlear implantation
surgery using a 24-channel device (cochlear-contour) in
the right ear. Twenty-ﬁve electrode rings were successfully
inserted and all 22 channels and 2 extracochlear electrodes
were found to be usable at the initial “switch on” of the
cochlear implant.
Clinical followup was quite stable: he referred sometimes
episodes of gastrointestinal pseudoobstruction and few
periods of scarce glycemic control; outcome of cochlear
implantation was good: postoperative neural response
telemetry (NRT), implant-evoked BAEP and middle latency
response (MLR) showed good responses. Eight years after
the surgery, the patient could use the telephone and was
satisﬁed with the improvement in communication due to
the cochlear implant.
4. Discussion
Hearing impairment is a common feature of mitochondrial
disease, either in isolation, or as a part of a complex multi-
system disorder, with the cochlea bearing the brunt of the
pathology. Ultimately, all forms of mitochondrial deafness
arise through a respiratory chain defect causing ATP deple-
tion, but it is not clear why hearing should be preferentially
aﬀected in some mitochondrial disorders and not in others,
norwhycochlearpathologycanvarybetweendiﬀerentdisor-
ders. There is clear evidence of a major environmental inﬂu-
ence in some forms of mitochondrial deafness, and the inter-
action between nuclear and mitochondrial genes appears to
be important [21].
The degree of hearing loss correlates well with the muta-
tion load in skeletal muscle [3], and the progressive nature
of the hearing loss may be related to the accumulation of
mutated mtDNA within the cochlea. Although this appears
to be the general trend, there are clear exceptions to the rule.
InonepatientwiththeA3243Gmutation,severehearingloss
was associated with low levels of mutated mtDNA in skeletal
muscle [22]. This may occur because of unequal segregation
of mutated mtDNA among diﬀerent tissues during early
development, so that occasionally, by chance, high levels are
presentinthecochlearprecursors,andlowerlevelsinskeletal
muscle precursor cells.
The percentage of mutated mtDNA undoubtedly con-
tributes to the clinical variability seen among patients, but
this does not provide the whole explanation. It is not cur-
rently known why certain maternal pedigrees transmitting
A3243Gtendtodevelopapuredeafness-diabetesphenotype,
whereas others only show ptosis and external ophthalmople-
gia, and yet others are aﬀected by severe multisystem MELAS
phenotype [23]. Additional genetic factors are likely to be
important, but have yet to be identiﬁes [21].
Our study considers only the syndromic form of mito-
chondrial SNHL, showing that the frequency of hearing loss
in our group of patients is the same of the most of studies
reported in literature [3, 21]; moreover, it suggests how this
form does not present diﬀerence about sex and age of onset
into each single group of diseases (data not shown). One
limit of our study is the retrospective analysis that does not
allow to deﬁne in patients without hearing loss if this deﬁcit
will develop in the future and does not give the real severity
of hearing loss within diﬀerent categories.
However, the study oﬀers important considerations,
like the relative low frequency of hearing loss in patients
with chronic progressive external ophthalmoplegia (CPEO)
(16%), which could be considered in most of cases a “pure”
myopathy, and, by contrast, the high frequency of hearing4 Genetics Research International
loss in patients aﬀected by mitochondrial neurogastroin-
testinal encephalomyopathy (MNGIE) (75%), in which the
diagnosis may be diﬃcult at the beginning and the presence
of hearing loss could orient clinicians in considering a
mitochondrial disease in the diﬀerential diagnosis [24].
The case presented in this study remarks the importance
to consider cochlear implant in patients with mitochondrial
SNHL. The patient suﬀered from hearing loss due to MELAS
syndrome; after cochlear implantation his quality of life
markedly improved and he could preserve his work.
Sincetheﬁrstrecordedcochlearimplantinapatientwith
Kearns-Sayre syndrome [25], many patients have success-
fully received implants [13]. In many ways, patients with
mitochondrial disease are “ideal” recipients of a cochlear
implant because the hearing loss develops well after speech
development, and often in isolation (as in patients with
diabetes and deafness due to A3243G, or non-syndromic
deafness due to A1555G). A systematic review of literature
(March 2003) identiﬁed 12 detailed descriptions of patients
with mitochondrial sensorineural deafness who had cochlear
implants [13]. All 12 cases had profound postlingual deaf-
ness. The age of onset of the deafness and the age at surgery
varied, but 58% were able to converse on the telephone
following the procedure, and the remainder had good open-
set speech recognition. There were no reported complica-
tions. The procedure should, however, only be undertaken
with caution, because the implantation procedure requires a
general anesthetic and takes a number of hours, and because
it is also important to consider the natural history of the
disorder in the individual patient. This is the case of MNGIE,
in which the mean age of death is 37 years [26], but the
presence of new therapeutic options gives hopes for patients
with this devastating neurodegenerative disorder and could
modify the prognosis. Very recently, Li and colleagues de-
scribed a successful multichannel cochlear implantation in
a 28-years-old MNGIE woman [27], conﬁrming the impor-
tance to consider and treat ear’s problems also in these types
of disorders.
In conclusion, individuals who harbour mtDNA muta-
tions may be at risk of developing severe hearing deﬁcit,
and these individuals should avoid ototoxic agents, such as
aminoglycoside antibiotics, which may further compromise
cochlear function [3].
Our study suggests that SNHL is an important feature
in mitochondrial disorders and should be considered in the
diagnostic workup and management of patients with sus-
pected mitochondrial disease. We found that cochlear im-
plantation in a patient with multisystem degenerative disease
greatly contributed to the patient’s quality of life and made it
possible for him to communicate with family members and
caregivers better than previously.
The results indicated that cochlear implantation can be
recommended for patients with MELAS syndrome and other
mitochondrial disorders, if they have residual retrocochlear
function.
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